Home/Pipeline/Keppra (levetiracetam)

Keppra (levetiracetam)

Epilepsy

ApprovedCommercial

Key Facts

Indication

Epilepsy

Phase

Approved

Status

Commercial

Company

UCB

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

View full company profile

Therapeutic Areas

Neurology Immunology Epilepsy Parkinson's Disease Multiple Sclerosis Rheumatoid Arthritis Psoriasis Inflammatory Diseases

Other Epilepsy Drugs

Drug	Company	Phase	Status
Soticlestat (TAK-935)	Takeda Pharmaceutical	Phase 3	Active
UCB4144	UCB	Phase 2	Active
NBI-921352	Neurocrine Biosciences	Phase 2	Active
Oxtellar XR®	Supernus Pharmaceuticals	Approved/Commercial	Marketed
ADX71149	Addex Therapeutics	Phase 2	Active (Partner-led)
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active